G1 Therapeutics Profit Margin

The latest profit margin for GTHX is -76.93% as of June 2024. That compares with -92.8% in the prior-year period — up 17.1% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside G1 Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GTHX's profit margin moved from -92.8% to -76.93% — a 17.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in G1 Therapeutics's valuation or profitability profile.

Against Healthcare companies, GTHX currently prints -76.93% for profit margin, while the sector average sits near 15.58%. That is roughly 593.7% below the sector mean. Large gaps often invite a closer look at G1 Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively G1 Therapeutics converts resources into returns. At -76.93%, GTHX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -92.8% in the prior-year period — up 17.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GTHX's profit margin (-76.93%), review year-over-year change from -92.8%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.